Starling Oncology, Inc. (STLNW) stock
STLNWNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLN
$0.03+0.00 (+10.87%)
Close on Oct 30, 2026Market cap $665.51MP/E –Yield –
Starling Oncology ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Starling Oncology's ebitda for the twelve months ending Jun 30, 2026 was -$19.28M. For fiscal 2025 it was -$29.14M. The highest annual figure on record is -$5.02M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$29.14M | – |
| FY2024 | Dec 31, 2024 | -$53.83M | – |
| FY2023 | Dec 31, 2023 | -$71.15M | – |
| FY2022 | Dec 31, 2022 | -$77.54M | – |
| FY2021 | Dec 31, 2021 | -$42.52M | – |
| FY2020 | Dec 31, 2020 | -$5.02M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.78M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.90M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.28M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.33M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.41M | – |
| Q1 FY2025 | Mar 31, 2025 | -$8.13M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.22M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.28M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.85M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.48M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.71M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.23M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.61M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.60M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.89M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.96M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.21M | – |
| Q1 FY2022 | Mar 31, 2022 | -$17.48M | – |
| Q4 FY2021 | Dec 31, 2021 | -$39.91M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.31M | – |
| Q2 FY2021 | Jun 30, 2021 | -$322.00K | – |
| Q1 FY2021 | Mar 31, 2021 | -$976.00K | – |